Bicoll News

Fractionation and Extraction Optimization of Compounds

New publication on molecules “Fractionation and Extraction Optimization of Potentially Valuable Compounds and Their Profiling in Six Varieties of Two Nicotiana Species”. There is an increasingly urgent call to shift industrial processes from fossil fuel feedstock to sustainable bio-based resources. …

Read more

Cybersecurity in Biotech and the Pharmaceutical Industry

In this fireside chat, Maria Lamottke talks to Christoph Eicken and focuses on the aspects of cybersecurity for biotech and pharmaceutical companies. Are there any special considerations when it comes to biotech and cybersecurity? Who is responsible for establishing and …

Read more

Bio-Convention 2022

Bicoll joins Bio 2022 to discuss research partnership opportunities in person. Visit us at German Pavilion – Booth 4607. #BIO2022 is back in-person! As there is no substitute for in-person collaboration, BIO is back this year offering ample opportunities to …

Read more

Medicinal Chemistry: Impact and role- Podcast

Gabriel Garcia, Ph.D. : Impact and Role of Medicinal Chemistry in the area of Drug Discovery: Stay ahead of the game. Gabriel Garcia has a Ph.D. in Organic Chemistry and has worked over the last 30 years in several academic …

Read more

Preliminary Pre-Clinical Evaluation of a Molecule With Anti-Seizure Effects

BICS01 Epilepsy ASD molecule

Despite the availability of around 30 anti-seizure drugs, drug-resistant epilepsy remains a significant clinical and societal burden. We report the first promising result of a new candidate BICS01.

Planegg / Martinsried (Germany) – January 7, 2022 – Bicoll, an expert in synthesizing new and relevant small molecules as starting points for accelerated drug development, worked together with its partners at the University College London, FutureNeuro, and Royal College of Surgeons to publish data for a promising anti-seizure drug candidate BICS01 in Frontiers in Neurology.

Read more

Bicoll GmbH Announces New Shareholder Trustee for Bicoll Biotechnology (Shanghai) Co. Ltd.

Planegg / Martinsried (Germany) – October 1, 2021, Bicoll GmbH approved Prof. Dr. Heinrich Arnold as shareholder trustee of its 100% daughter company Bicoll Biotechnology (Shanghai) Co. Ltd.

Bicoll Group is delighted to welcome such a renowned digital innovation and transformation guru and entrepreneurial mind such as Prof. Dr. Heinrich Arnold. Managing Director of Bicoll, Dr. Kai Lamottke, states: “Bicoll will definitely enormously profit from Dr. Arnold 20 years professional competence in different fields, such as supervision of start-ups and digital transformation knowledge. It is an asset to work with him.”

Read more

Research Taxation Support for German Entities: Forschungszulage

Forschungszulage in Deutschland

Seit dem 01.01.2020 bekommen Unternehmen mit Sitz in Deutschland steuerliche Begünstigungen für ihre Forschungsausgaben. Auch die Auftragsforschung darf zu 15% geltend gemacht werden. Das bedeutet, einen Auftrag bei Bicoll koennen Unternehmen nun zu 15% als Forschungszulage zurückerstattet bekommen. Seit 20 …

Read more

Bicoll Celebrates 20th Anniversary

Bicoll celebrates 20 year anniversary

This year marks the 20th anniversary of Bicoll. On November 29th, 2000 we embarked on this exciting journey to deliver research services and natural compound libraries, and enable our partners to develop new effective drugs for patients. We would like …

Read more